Table 2.
Pharmacokinetic parameters of distribution and elimination of budesonide and fluticasone after intravenous administration of 200 µg, respectively.
| Substance | Subjects | n | Dose (nmol)* | t½ (h) | AUC (nmol l−1 h) | MRT (h) | CL (ml min−1) | Vss (l) |
|---|---|---|---|---|---|---|---|---|
| Budesonide | Healthy | 13 | 406 (49) | 4.4 (3.7; 5.4) | 5.0 (4.5; 5.6) | 3.5 (3.0; 4.0) | 1334 (1213; 1466) | 280 (245; 321) |
| With asthma | 8 | 397 (24) | 4.6 (3.5; 6.1) | 4.9 (4.2; 5.8) | 3.8 (3.1; 4.7) | 1344 (1167; 1548) | 310 (269; 357) | |
| Total | 21 | 403 (39) | 4.5 (3.9; 5.2) | 5.0 (4.6; 5.4) | 3.6 (3.3; 4.0) | 1338 (1245; 1437) | 291 (265; 320) | |
| Fluticasone | Healthy | 13 | 377 (19) | 12.7 (9.4; 17.2) | 5.0 (4.6; 5.5) | 8.0 (5.8; 11.0) | 1245 (1140; 1359) | 599 (448; 800) |
| With asthma | 8 | 386 (26) | 12.0 (9.0; 16.1) | 4.5 (3.6; 5.7) | 7.1 (5.3; 9.5) | 1418 (1134; 1775) | 607 (475; 777) | |
| Total | 21 | 380 (22) | 12.5 (10.2; 15.2) | 4.8 (4.4; 5.3) | 7.7 (6.2; 9.5) | 1308 (1192; 1436) | 602 (500; 726) |
Values given as geometric means (95% CI).
*
Arithmetic mean (s.d.).
t½=half-life; AUC=area under the curve of plasma concentration vs time; MRT=mean residence time; CL=clearance; Vss=volume of distribution at steady state.